All
Carfilzomib Phase III ENDEAVOR Data Submitted for FDA Approval in Myeloma
July 24th 2015A supplemental new drug application (sNDA) was recently submitted for carfilzomib (Kyprolis) in combination with dexamethasone for patients who have relapsed multiple myeloma, following previous treatment with at least one therapy.
Breakthrough Designation Granted to BRAF/MEK Combo for BRAF V600 NSCLC
July 23rd 2015Breakthrough therapy designation has been granted by the US Food and Drug Adminstration (FDA) to the combination of the BRAF inhibitor dabrafenib (Tafinlar) and the MEK inhibitor trametinib (Mekinist) as treatment for patients with BRAF V600E-mutant non–small cell lung cancer
Pembrolizumab (Keytruda) Approved by European Commission for Advanced Melanoma
July 23rd 2015The PD-1 inhibitor pembrolizumab (Keytruda) was recently approved by the European Commission for the treatment of adult patients who have unresectable or metastatic melanoma in the first-line and previously treated settings, based on data from three clinical trials that evaluated the medication in over 1500 patients.
Case Shows Dramatic Antitumor Effects With Immunotherapy in Melanoma
July 23rd 2015A letter to the editor in the New England Journal of Medicine from notable researchers at Memorial Sloan Kettering reported a case of complete remission of metastatic melanoma in a patient treated with single doses of ipiliumab and nivolumab.
Atezolizumab Shows Tumor Reduction for Bladder Cancer in the Second Line
July 22nd 2015The anti-PDL1 agent, atezolizumab (MPDL3280A) may effectively shrink tumors in patients with locally advanced or metastatic urothelial bladder cancer in the second-line setting, according to a statement from the immunotherapy’s developer, Genentech.
NY-ESO-1 TCR Produces Positive Results in Patients With Multiple Myeloma
July 22nd 2015Data from a phase I/II single-arm trial of the NY-ESO-1 T-Cell Receptor (TCR) therapy, recently published in Nature Medicine, is the first to show feasibility and antitumor responses in patients who have multiple myeloma.
European Commission Approves Nivolumab for Patients with Squamous NSCLC
July 21st 2015Nivolumab (Opdivo) was recently approved by the European Commission as a treatment for patients who have locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), following prior chemotherapy, based on findings from the phase III Checkmate-017, as well as the phase II Checkmate-063 trials.
PIK3CA/PTEN Linked to Extended PFS in Patients With HER2-Positive Breast Cancer
July 21st 2015A recent combined analysis of the BOLERO-1 and -3 studies showed that PIK3CA mutations and low/no expression of PTEN linked to an extension in progression-free survival (PFS) for patients who have metastatic HER2-positive breast cancer and are treated with a combination of everolimus, trastuzumab, and paclitaxel.
Cabozantinib (Cometriq) Improves PFS and OS in Patients With mRCC
July 20th 2015Results from the phase III METEOR study showed that treatment with cabozantinib (Cometriq) improved progression-free survival (PFS) and overall survival (OS) compared with everolimus (Afinitor) in previously treated patients with metastatic renal cell carcinoma (mRCC).
Efficacy of Blinatumomab Presented in Phase II Ph+ ALL Study
July 20th 2015According to findings from a phase II study released by Amgen, monotherapy with blinatumomab (Blincyto) showed promising complete remission (CR) or CR with partial hematological recovery (CRh) rates in adult patients with relapsed or refractory Philadelphia chromosome-positive (Ph+) B cell precursor acute lymphoblastic leukemia (ALL).
Epigenetic-Active Agents May Improve Sensitivity to Temozolomide in Melanoma
July 16th 2015Using treatments that target epigenetic pathways, including the DNA methyltransferase inhibitor decitabine and the histone deacetylase (HDAC) inhibitor panobinostat, investigators hoped to improve the sensitivity of melanoma cells to the alkylating agent temozolomide.
FDA to Review Ixazomib in Relapsed and/or Refractory Multiple Myeloma
July 16th 2015Takeda released a statement saying that a new drug application was submitted for ixazomib (MLN9708), an oral proteasome inhibitor, used in combination with lenalidomide and dexamethasone, as a treatment for patients with relapsed and/or refractory multiple myeloma.
Gefitinib (Iressa) FDA Approved in Patients With EGFR-Positive NSCLC
July 14th 2015Gefitinib (Iressa) was recently approved by the FDA for the frontline treatment of patients who have metastatic, EGFR-positive non-small cell lung cancer (NSCLC) with an exon 19 deletion or exon 21 (L858R) substitution.
Updates on New and Emerging Therapies for Neuroendocrine Tumors
July 13th 2015This case-based program is designed to educate medical oncologists, surgical oncologists, radiation oncologists, hem-oncs, and other allied health professionals on updates on new and emerging therapies for neuroendocrine tumors.
Necitumumab for Patients With Squamous NSCLC Supported by ODAC
July 10th 2015The approval of necitumumab, combined with gemcitabine and cisplatin for the first-line treatment of patients who have locally advanced or metastatic squamous non-small cell lung cancer (NSCLC), was supported by FDA’s Oncologic Drugs Advisory Committee (ODAC).
Targeting the Warburg Effect May Pave Way for New Class of Anticancer Agents
July 8th 2015Researchers from Saint Louis University have developed a new class of anticancer drugs that potently reduce tumor growth and survival by targeting two energy sources, the Warburg effect (glycolysis) and lipogenesis.
Combined Analysis of CORRECT and CONCUR Confirms Survival Benefit of Regorafenib
July 7th 2015The survival benefit observed with regorafenib over placebo in Asian patients who had been previously treated for mCRC in the international phase III CORRECT trial was confirmed by the phase III CONCUR trial.
Trial Evaluates Antibody-Drug Conjugate in Advanced Triple-Negative Breast Cancer
July 7th 2015An ongoing randomized trial in triple-negative breast cancer (TNBC) is evaluating the safety and efficacy of an antibody-drug conjugate that targets glycoprotein NMB (gpNMB), which is associated with reduced metastasis-free and overall survival.
PI3K Inhibition May Fuel Cancer Rather Than Fight It
July 6th 2015A study, by M. Cecilia Cano, PhD, et al at the Wistar Institute, Philadelphia, has shown that monotherapy treatment with PI3K inhibitors may worsen a patient’s cancer by causing more aggressive tumor cell behavior and increasing the likelihood of metastases to other organs.